CIA
SAGE

Capital Impact Advisors’s Sage Therapeutics SAGE Stock Holding History

Capital Impact Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-7,768
Closed -$397K – 213
2016
Q4 		$397K Hold
7,768
– – 0.16% 208
2016
Q3 		$358K Hold
7,768
– – 0.15% 211
2016
Q2 		$234K Hold
7,768
– – 0.11% 213
2016
Q1 		$249K Hold
7,768
– – 0.12% 214
2015
Q4 		$453K Hold
7,768
– – 0.22% 207
2015
Q3 		$329K Hold
7,768
– – 0.17% 200
2015
Q2 		$567K Hold
7,768
– – 0.26% 179
2015
Q1 		$390K Buy
+7,768
New +$334K 0.18% 216

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Capital Impact Advisors's SAGE Position: Q1 2017 in Review

Capital Impact Advisors sold out of Sage Therapeutics (SAGE) in Q1 2017, closing a stake of 7,768 shares — an estimated $397K sold.

Capital Impact Advisors first reported a position in SAGE in Q1 2015 and held it in 8 quarters. The position peaked at $567K in Q2 2015. 190 funds tracked by Wall St. Rank hold SAGE as of Q1 2017.

  • Capital Impact Advisors reported no remaining Sage Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Capital Impact Advisors sold 7,768 Sage Therapeutics shares in Q1 2017, an estimated $397K.
  • Capital Impact Advisors first reported a position in Sage Therapeutics in Q1 2015 and held it in 8 quarters.
  • Capital Impact Advisors's Sage Therapeutics position peaked at $567K in Q2 2015.
  • 190 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2017.

Based on Capital Impact Advisors's 13F filing for Q1 2017, filed 19 Apr 2017.